drugset / Trial / NCT07302841
Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, open-label, single-arm clinical trial evaluating the safety and efficacy of tunlametinib in combination with gemcitabine/albumin-bound paclitaxel and an EGFR monoclonal antibody as first-line therapy in treatment-naive subjects with advanced pancreatic cancer.
Timeline
- Start
- 2026-01-20
- Primary completion
- 2027-06-20
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tunlametinib | Small molecule | 9 mg | Oral |
| Background | Cetuximab β | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |